I know this is quite a specialist subject but I thought there might be some pharma patent experts here.
I am trying to understand why when you apply for a patent for a particular therapeutic compound, patent applications tend to explicitly list many compounds (often produced by other companies) that the compound the subject matter of the application may be be combined with in the future.
For example, here is a patent application for anti-HIV antibodies:
In it they write:
The antibody or fragment thereof disclosed herein can be combined with one or more additional therapeutic agents in any dosage of the antibody or fragment thereof (eg, 50 mg to 1000 mg of compound). Also, the antibody or fragment thereof disclosed herein may be used at any dosage of the antibody or fragment thereof (eg, about 0.1 mg to about 50 mg, or 50 mg to 4000 mg of compound per kg body weight of the subject), It may be combined with one or more additional therapeutic agents.
In one embodiment, one or more of the antibodies or fragments thereof or pharmaceutically acceptable salts thereof disclosed herein (eg, 1, 2, 3, 1, 2 or 3, Or one to three) additional therapeutic agents and pharmaceutical compositions containing them in combination with a pharmaceutically acceptable carrier, diluent or additive are provided.
In one embodiment, one or more (eg, one, two, three, one or two) of the antibodies or fragments thereof or pharmaceutically acceptable salts thereof disclosed herein, Or one to three) additional therapeutic agents are provided
They then go on to list almost every known HIV therapeutic that exists.
- Why do they need to list all the potential drugs that the compound (the subject of the patent application) may possibly be combined with to form a treatment? What would the risk be if they didn't do this?